o
|
Rule 13d-1(b)
|
o
|
Rule 13d-1(c)
|
x
|
Rule 13d-1(d)
|
CUSIP No. M96883109
|
13G
|
Page 2 of 8 Pages
|
1. |
NAMES OF REPORTING PERSONS
Aurum Ventures M.K.I. Ltd.
|
||
2. |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) o
|
||
3. |
SEC USE ONLY
|
||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION
Israel
|
||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5. |
SOLE VOTING POWER
4,254,778
|
|
6. |
SHARED VOTING POWER
0
|
||
7. |
SOLE DISPOSITIVE POWER
4,254,778
|
||
8. |
SHARED DISPOSITIVE POWER
0
|
||
9. |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,254,778
|
||
10. |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)
|
||
11. |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
21.4% (1)
|
||
12. |
TYPE OF REPORTING PERSON (see instructions)
CO
|
(1)
|
Percentage is based on 19,898,674 Ordinary Shares of the Issuer that were issued and outstanding as of January 4, 2015 (which information appeared in the Issuer’s proxy statement, dated January 6, 2015, for its extraordinary general meeting of shareholders that took place on February 11, 2015, which was annexed as Exhibit 99.1 to the Report of Foreign Private Issuer on Form 6-K furnished by the Issuer to the SEC on January 6, 2015).
|
CUSIP No. M96883109
|
13G
|
Page 3 of 8 Pages
|
1. |
NAMES OF REPORTING PERSONS
Morris Kahn
|
||
2. |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) o
|
||
3. |
SEC USE ONLY
|
||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION
|
||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5. |
SOLE VOTING POWER
|
|
6. |
SHARED VOTING POWER
4,254,778
|
||
7. |
SOLE DISPOSITIVE POWER
0
|
||
8. |
SHARED DISPOSITIVE POWER
4,254,778
|
||
9. |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,254,778
|
||
10. |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)
|
||
11. |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
21.4% (1)
|
||
12. |
TYPE OF REPORTING PERSON (see instructions)
IN
|
(1)
|
Percentage is based on 19,898,674 Ordinary Shares of the Issuer that were issued and outstanding as of January 4, 2015 (which information appeared in the Issuer’s proxy statement, dated January 6, 2015, for its extraordinary general meeting of shareholders that took place on February 11, 2015, which was annexed as Exhibit 99.1 to the Report of Foreign Private Issuer on Form 6-K furnished by the Issuer to the SEC on January 6, 2015).
|
(a)
|
Name of Issuer
Vascular Biogenics Ltd.
|
(b)
|
Address of Issuer’s Principal Executive Offices
6 Jonathan Netanyahu St., Or Yehuda, Israel 60376
|
(a)
|
Name of Person Filing:
This Statement of Beneficial Ownership on Schedule 13G (this “Statement”), is being filed by each of:
(i) Aurum Ventures M.K.I. Ltd. (the “Reporting Entity”)
(ii) Morris Kahn (the “Reporting Individual”)
The Reporting Individual is the sole shareholder of the Reporting Entity. The Reporting Entity and the Reporting Individual are referred to herein collectively as the “Reporting Persons”.
|
(b)
|
Address of Principal Business Office or, if None, Residence:
The principal business office of each of the Reporting Persons is c/o Aurum Group, 16 Abba Hillel Road
Ramat Gan 5250608, Israel
|
(c)
|
Citizenship:
The Reporting Entity is organized in Israel. The Reporting Individual is a citizen of the State of Israel.
|
(d)
|
Title of Class of Securities
Ordinary Shares, New Israeli Shekel (“NIS”) 0.01 par value per share (“Ordinary Shares”)
|
(e)
|
CUSIP Number
M96883109
|
(a)
|
o
|
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
|
(b)
|
o
|
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
|
(c)
|
o
|
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
|
(d)
|
o
|
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
|
(e)
|
o
|
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
|
(f)
|
o
|
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
|
(g)
|
o
|
A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
|
(h)
|
o
|
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
|
(i)
|
o
|
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
|
(j)
|
o
|
Group, in accordance with §240.13d-1(b)(1)(ii)(J).
|
(a)
|
Amount beneficially owned: 4,254,778 Ordinary Shares
|
(b)
|
Percent of class: 21.4%.*
*Such percentage is based on 19,898,674 Ordinary Shares of the Issuer that were issued and outstanding as of January 4, 2015 (which information appeared in the Issuer’s proxy statement, dated January 6, 2015, for its extraordinary general meeting of shareholders that took place on February 11, 2015, which was annexed as Exhibit 99.1 to the Report of Foreign Private Issuer on Form 6-K furnished by the Issuer to the SEC on January 6, 2015).
|
|||
(c)
|
Number of shares as to which the person has:
|
|||
(i)
|
Sole power to vote or to direct the vote: Reporting Entity: 4,254,778
Reporting Individual: 0
|
|||
(ii)
|
Shared power to vote or to direct the vote: Reporting Entity: 0
Reporting Individual: 4,254,778
|
|||
(iii)
|
Sole power to dispose or to direct the disposition of: Reporting Entity: 4,254,778
Reporting Individual: 0
|
|||
(iv)
|
Shared power to dispose or to direct the disposition of: Reporting Entity: 0
Reporting Individual: 4,254,778
|
AURUM VENTURES M.K.I. LTD.
By: /s/ Nili Lesnik
Name: Nili Lesnik
Title: Chief Executive Officer
By: /s/ Dan Gelvan
Name: Dan Gelvan
Title: Managing Director- Life Sciences
Date: February 17, 2015
/s/ Morris Kahn
MORRIS KAHN
Date: February 17, 2015
|
AURUM VENTURES M.K.I. LTD.
By: /s/ Nili Lesnik
Name: Nili Lesnik
Title: Chief Executive Officer
By: /s/ Dan Gelvan
Name: Dan Gelvan
Title: Managing Director- Life Sciences
Date: February 17, 2015
/s/ Morris Kahn
MORRIS KAHN
Date: February 17, 2015
|